Biocon announced today that its supplemental Biologics License Application (sBLA) for its biosimilar pegfilgrastim, Fulphila, filed with partner Mylan, has been approved by the FDA.
Biocon announced today that its supplemental Biologics License Application (sBLA) for its biosimilar pegfilgrastim, Fulphila, filed with partner Mylan, has been approved by the FDA.
The additional approval relates to Biocon’s new manufacturing facility for the biosimilar in Bengaluru, India. The FDA conducted its preapproval inspection of the new drug substance manufacturing facility from September 10 to September 19 of this year.
The new facility will allow Biocon and Mylan to scale up capacity “multi-fold,” said the company in a statement, to address the growing market for the biosimilar in the United States and around the world. Fulphila, the first biosimilar pegfilgrastim to launch in the United States commercially, currently competes with Coherus Biosciences’ Udencya and Sandoz’s Ziextenzo for a share of the brand-name Neulasta’s market.
Biocon’s chief executive officer, Christiane Hamacher, PhD, said in a statement announcing the sBLA’s approval that “This is a significant milepost in our journey,” and that the company expects to serve 5 million patients—and cross a revenue threshold of $1 billion—by financial year 2022. She also pointed to the benefits for the US healthcare system, saying that biosimilar penetration will enable better cost saving and greater patient access to high-quality treatment.
News of the progress for Fulphila comes shortly after Biocon announced that the FDA had issued an establishment inspection report for its Bengaluru facility and that the company would now be in a position to launch its long-awaited trastuzumab biosimilar, Ogivri, which is also approved by the FDA, “soon.”
Biocon, which also makes biosimilar insulins, has also recently announced its plans to improve access to high-quality insulins for patients with diabetes worldwide. As part of its universal access initiative, the company has said that it will offer human recombinant insulin at a cost of less than 10 cents per day for government procurement agencies in low- and middle-income countries.
Biocon will further discuss its access program during next week’s International Diabetes Federation Congress in Busan, South Korea.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.